🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At this week’s 43rd Annual J.P. Morgan Healthcare Conference, our CEO Matthew Klein, M.D., shared insights on how PTC’s successful execution in 2024 has set the stage for a bright and successful future in 2025 and beyond. Hear the full story: ir.ptcbio.com/events-present…

We're incredibly proud to be named one of BioNJ's 2025 Innovator Award Honorees in recognition of the first and only FDA-approved gene therapy for treating children and adults with #AADCdeficiency.

PTC will announce fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27. Learn more: bit.ly/3Qhg145

The FDA has accepted our NDA for vatiquinone to treat Friedreich's ataxia. Our application has been granted Priority Review and assigned a PDUFA date of Aug. 19, 2025. This is our 4th NDA submitted and accepted for review within the last year. Learn more: bit.ly/4b31Qtf

Today, our CEO Matthew B. Klein, M.D. shared an update about PTC’s outstanding year of execution in 2024. From record revenue to key regulatory milestones, we achieved remarkable success across all areas of the business last year. Learn more: bit.ly/3DkpeWr

On this #RareDiseaseDay, we celebrate the inspiring rare disease community who motivate us to excel. We’re proud to raise awareness of the 6,000+ identified rare diseases and more than 300 million people worldwide living with a rare condition.

PTC will be participating in the TD Cowen 45th Annual Health Care 2025 Conference today, March 4 at 11:10 a.m. ET. Tune in to our fireside chat to hear our latest updates: bit.ly/4iH7VOH

PTC will be participating in the Barclays 27th Annual Global Healthcare Conference today, March 11 at 12:30 p.m. ET. Tune in to our fireside chat to hear our latest updates: bit.ly/4kIkvPd

We're honored to be named one of Gallup's 2025 Exceptional Workplace Award winners for Strengths Development for the fourth time! Learn more: bit.ly/4hvd239

We're excited to be onsite at this year's #ACMGMtg25 in Los Angeles to to share data on our #PKU and #AADCd programs.

It's been a productive week for us at #ACMGmtg25. We presented new data from our sepiapterin Phase 3 APHENITY trial and open-label extension study demonstrating the potential to treat children and adults living with #PKU. Learn more: bit.ly/4bEWWCV

Our teams were thrilled to connect with the #Friedreichsataxia (FA) community at the 2025 #MDAConference and share data from our #FA program. We're proud to be developing a potential treatment for children and adults living with this rare disorder.

We are pioneering innovative treatments for patients around the world and are proud to share that our #genetherapy for AADC deficiency (#AADCd) has received approval in Hong Kong.

Today we announced that our leaders will report the company's first-quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6 at 4:30 p.m. ET. Learn more: bit.ly/42wwiYD

PTC's leaders will present at four upcoming investor conferences this May and June. Learn more: bit.ly/3S4PB6B

Today, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on PTC's treatment option Sephience (sepiapterin) for adults and children with phenylketonuria (PKU). Learn more: bit.ly/4jUzQex

Today we announced our first quarter 2025 earnings, highlighting a promising start thanks to strong revenue performance and a steady progression of global launch activities following the recent positive CHMP opinion for our potential PKU treatment. bit.ly/3RROoQc

We invite you to hear from PTC's leaders at the Bank of America Securities 2025 Health Care Conference today, May 13. Tune in to our live webcast at 1 p.m. ET (10 a.m. PT) to learn more about the company's latest updates: bit.ly/42vhqc9

Our leaders will be participating in the RBC Capital Markets Global Healthcare Conference 2025 today, May 20 at 2:05 p.m. ET. Tune in to our fireside chat to hear our latest updates: bit.ly/42vhqc9

Our leaders will participate in the William Blair 45th Annual Growth Stock Conference 2025 today June 3 at 10:20 a.m. ET. Tune in to our fireside chat to hear our latest updates: ir.ptcbio.com/events-present…